Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|March 29, 2022
[Diagnosis and treatment of COVID-19 in intensive care units]Wolfgang Hoepler, Marianna Traugott, Alexander Zoufaly, et al.
Expert Opinion on Investigational Drugs|February 10, 2025
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluationKatharina A Mayer, Klemens Budde, Martina Schatzl, et al.
Kidney International Reports|November 24, 2025
The Effects of Clazakizumab on Peripheral Blood and Kidney Transcriptomes in Patients With Late Antibody-Mediated RejectionRoy Zhang, Colin Y C Lee, Martina Schatzl, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|July 9, 2024
Natural Killer Cell Presence in Antibody-Mediated RejectionMatthias Diebold, Evan A Farkash, Jenna Barnes, et al.
Transplantation|October 15, 2024
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort StudyMatthias Diebold, Hannes Vietzen, Martina Schatzl, et al.
The Lancet Regional Health. Europe|July 19, 2026
Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extensionKatharina A Mayer, Matthias Diebold, Eva V Schrezenmeier, et al.
The New England Journal of Medicine|May 28, 2024
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated RejectionKatharina A Mayer, Eva Schrezenmeier, Matthias Diebold, et al.
Pageof 1